Amicus Therapeutics to Announce Third Quarter 2012 Financial Results on November 5, 2012

Amicus Therapeutics to Announce Third Quarter 2012 Financial Results on
November 5, 2012

Webcast and Conference Call at 5:00 p.m. ET

CRANBURY, N.J., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing
therapies for rare and orphan diseases, today announced a conference call and
live audio webcast on Monday, November 5, 2012 at 5:00 p.m. ET to discuss
financial results for the third quarter ended September 30, 2012.

The call will be hosted by John F. Crowley, Chairman and Chief Executive
Officer. He will be joined on the call by additional members of the Amicus
management team. Interested participants and investors may access the
conference call at 5:00 p.m. ET by dialing 877-303-5859 (U.S./Canada) or
678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the
Amicus Therapeutics corporate web site at
http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days.
Web participants are encouraged to go to the web site 15 minutes prior to the
start of the call to register, download and install any necessary software.

The slide presentation for the conference call/webcast will also be available
at http://ir.amicustherapeutics.com/events.cfm.

A telephonic replay of the call will be available for seven days beginning at
8:00 p.m. ET on November 5, 2012. Access numbers for this replay are
855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code
64424986.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of developing therapies for rare and orphan diseases. The Company is
developing orally-administered, small molecule drugs called pharmacological
chaperones, a novel, first-in-class approach to treating a broad range of
human genetic diseases. Amicus' late-stage programs for lysosomal storage
disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease;
migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase
2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe
disease.

FOLD-G

CONTACT: Investors/Media:
         Sara Pellegrino
         spellegrino@amicusrx.com
         (609) 662-5044